Wed, March 10, 2021
Tue, March 9, 2021
Mon, March 8, 2021

Paul Matteis Downgraded (ACAD) to Hold and Decreased Target to $27 on, Mar 9th, 2021

Paul Matteis of Stifel, Downgraded "ACADIA Pharmaceuticals Inc." (ACAD) to Hold and Decreased Target from $68 to $27 on, Mar 9th, 2021.

Paul has made no other calls on ACAD in the last 4 months.



There is 1 other peer that has a rating on ACAD. Out of the 1 peers that are also analyzing ACAD, 0 agree with Paul's Rating of Hold.



This is the rating of the analyst that currently disagrees with Paul


  • Vamil Divan of "Mizuho" Initiated at Strong Buy and Held Target at $69 on, Wednesday, December 16th, 2020